Cleveland BioLabs
Cleveland BioLabs, Inc. is a biopharmaceutical company focused on developing innovative treatments that activate the immune system to address critical medical needs, particularly in oncology and radiation protection. Established in 2003 and headquartered in Buffalo, New York, the company utilizes a proprietary platform of toll-like immune receptor activators with applications in mitigating radiation injury and enhancing cancer therapies. Its lead product candidate, entolimod, is an immune-stimulatory agent designed as a medical countermeasure against acute radiation syndrome and for various oncology applications. Additionally, Cleveland BioLabs is advancing Mobilan, a recombinant adenovirus aimed at promoting TLR5 expression. The company collaborates with notable institutions such as the Cleveland Clinic and Roswell Park Cancer Institute to further its research and development efforts.
Panacela Labs, Inc. is a joint venture company founded in 2011 by Cleveland BioLabs (Nasdaq:CBLI), a clinical-stage biotechnology company with a focus on oncology and orphan drug development, and Open Joint Stock Company “RUSNANO”, the largest Russian investment company, in collaboration with Roswell Park Cancer Institute, Children’s Cancer Institute of Australia and Cleveland Clinic Foundation. Panacela Labs is 54.6% owned by Cleveland BioLabs. Panacela Labs has residency in the Innovation Center "Skolkovo".
Panacela Labs, Inc. is a joint venture company founded in 2011 by Cleveland BioLabs (Nasdaq:CBLI), a clinical-stage biotechnology company with a focus on oncology and orphan drug development, and Open Joint Stock Company “RUSNANO”, the largest Russian investment company, in collaboration with Roswell Park Cancer Institute, Children’s Cancer Institute of Australia and Cleveland Clinic Foundation. Panacela Labs is 54.6% owned by Cleveland BioLabs. Panacela Labs has residency in the Innovation Center "Skolkovo".
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.